Suchergebnisse - "Hsiehchen, David"

PubPharm (70)

1

Tissue-specific thresholds of mutation burden associated with anti-PD-1/L1 therapy benefit and prognosis in microsatellite-stable cancers

enthalten in: Nature cancer | 2024

von Muquith, M. | Espinoza, M. | Elliott, A. | +17

2

The phosphatidylserine targeting antibody bavituximab plus pembrolizumab in unresectable hepatocellular carcinoma : a phase 2 trial

enthalten in: Nature communications | 2024

von Hsiehchen, D. | Beg, M. | Kainthla, R. | +21

3

Landscape and Saturation Analysis of Mutations Associated With Race in Cancer Genomes by Clinical Sequencing

enthalten in: The oncologist | 2024

von Muquith, M. | Hsiehchen, D.

4

Role of Neoadjuvant Therapy Prior to Curative Resection in Hepatocellular Carcinoma

enthalten in: Surgical oncology clinics of North America | 2024

von Whitham, Z. | Hsiehchen, D.

5

pan-MHC and cross-Species Prediction of T Cell Receptor-Antigen Binding

enthalten in: bioRxiv.org | 2023

von Han, Y. | Yang, Y. | Tian, Y. | +30

6

pan-MHC and cross-Species Prediction of T Cell Receptor-Antigen Binding

enthalten in: bioRxiv : the preprint server for biology | 2023

von Han, Y. | Yang, Y. | Tian, Y. | +30

7

Surrogate and modified endpoints for immunotherapy in advanced hepatocellular carcinoma

enthalten in: Hepatology (Baltimore, Md.) | 2023

von Lim, M. | Muquith, M. | Miramontes, B. | +4

8

Lengthy and Variable Delays in Oncology Drug Coverage Determination

enthalten in: JAMA oncology | 2023

von Haque, W. | Rana, I. | Zahid, S. | +1

9

Author Correction : Genetic features and therapeutic relevance of emergent circulating tumor DNA alterations in refractory non-colorectal gastrointestinal cancers

enthalten in: Nature communications | 2023

von Hsiehchen, D. | Bucheit, L. | Yang, D. | +6

ErratumFor: Nat Commun. 2022 Dec 3;13(1):7477. - PMID 36463294

10

Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050) : a randomised, open-label, multicentre, phase 3 trial

enthalten in: Lancet (London, England) | 2023

von Qin, S. | Chen, M. | Cheng, A. | +122

CommentIn: Lancet. 2023 Nov 18;402(10415):1806-1807. - PMID 37883983

1
2
3
4
5
6
7
Nächster »
[7]